Key Highlights

  • ImmuPharma (LSE: IMM) shares were shown 8.9% higher in a snapshot of top UK gainers, though they remain around 42% below the 6p price of a recent capital raise.
  • The company reported a supportive first patent examination report on P140 and continues to target a value-enhancing licensing agreement for the drug during 2026.
  • FY2025 losses narrowed to £1.8m from £2.5m, with cash of just £1.4m at year-end before a subsequent £6.47m share raise at 6p per share.
  • The raise expanded the share count to roughly 623.9m shares, leaving a market capitalisation of around £22m and negative shareholders' funds.
  • A second pipeline asset, Kapiglucagon, is advancing through IND-enabling studies for metabolic disease and Type 1 diabetes.

A perennial small-cap turnaround story stirs again

Few names on London's junior market carry as much history, and as many bruises, as ImmuPharma (LSE: IMM). The clinical-stage drug developer, best known for its autoimmune candidate P140, once traded as a hopeful mid-cap on the strength of its lupus programme before a high-profile trial disappointment left it languishing among the forgotten cohort of AIM biotechs. Now, with a refreshed balance sheet, incremental patent progress and management openly targeting a licensing transaction in 2026, the shares have flickered back into view. A recent appearance among the day's leading risers has prompted the obvious question: is the market beginning to reappraise a stock many had written off?

What the snapshot showed

ImmuPharma featured on a list of top UK gainers, where the shares were shown 8.9% higher in the snapshot. For a company of this size, a move of that magnitude requires only modest buying, and it should be read as a single moment in a volatile trading history rather than a durable trend. It is worth stressing that this figure reflects the snapshot at the time it was captured, not a live or current price. Context matters: shares closed at 3.48p on 3 July 2026, some 42% below the 6p price at which the company raised fresh capital earlier in the year, a reminder that recent bursts of enthusiasm sit against a backdrop of persistent share-price weakness.

Recent developments around P140

The activity coincides with a steady drumbeat of updates on P140, the peptide therapeutic ImmuPharma is repositioning for autoimmune conditions. The company has reported a supportive first Combined Search and Examination Report on a UK patent application filed in September 2025, covering a companion diagnostic and precision-treatment approach, and says it intends to pursue broader international protection via a Patent Cooperation Treaty filing. Management has also pointed to new mechanistic data and a validation study for its diagnostic tool, alongside a scientific manuscript being prepared for peer-reviewed submission. Crucially, the leadership team has been active on the partnering circuit, including at the Bio-Europe Spring conference, as it works towards what it describes as a value-enhancing licensing agreement for P140 during 2026. Alongside this, ImmuPharma is advancing Kapiglucagon, a glucagon prodrug aimed at metabolic disease and Type 1 diabetes, through IND-enabling studies while evaluating a 505(b)(2) regulatory pathway in the United States.

The financial and operational position

The fundamentals remain those of an early-stage developer with little income and a habit of consuming cash. For the year ended 31 December 2025, published on 27 May 2026, ImmuPharma reported a loss of £1.8m, narrowed from £2.5m the prior year, with research and development spending of roughly £1.3m and broadly stable operating costs. Cash stood at just £1.4m at the year-end. That figure predated a fundraising completed in the following months: a £6.47m share raise struck at 6p per share, which included a subscription by Lanstead Capital and a retail offer ahead of the admission of the new shares. The raise materially improved liquidity from a low base, but it also expanded the share count to roughly 623.9m shares, leaving a market capitalisation in the region of £22m. The company has flagged weak financial fundamentals, including minimal revenue, ongoing losses, continued cash burn and negative shareholders' funds, the classic profile of a business dependent on external funding.

Why investors may be paying attention

The renewed interest is not hard to rationalise, even if it is speculative. ImmuPharma is a low-priced, tightly-followed stock where any hint of progress towards a commercial deal can move the price sharply. The prospect of a 2026 licensing agreement for P140 offers a binary, potentially transformational outcome that appeals to risk-tolerant traders, while the recent fundraising has, at least temporarily, addressed the most immediate question hanging over any micro-cap: whether it has the cash to keep going. The addition of Kapiglucagon gives the story a second string, broadening the pipeline beyond a single asset.

The bull case

For believers, the appeal rests on optionality. A licensing deal, should one materialise on acceptable terms, could bring upfront payments, milestones and validation from a larger partner, none of which is currently reflected in a valuation of around £22m. Patent progress strengthens the intellectual-property position that any licensee would be buying into, and the pivot towards a companion diagnostic and precision-medicine framing is an attempt to differentiate P140 in a crowded autoimmune field. With a strengthened cash position following the raise, management has bought itself time to pursue partnering discussions from a position of relative stability rather than distress.

The risks and uncertainties

Against that, the risks are substantial and should not be understated. There is no guarantee a licensing deal will be signed in 2026, or at all, and the company itself frames such an agreement as an aspiration rather than a certainty. The shares trade well below the recent placing price, evidence that the market remains sceptical. Negative shareholders' funds, recurring losses and cash burn mean further dilution is a realistic prospect if a deal proves elusive, and holders have already seen their stakes diluted by the latest raise. Clinical and regulatory milestones for both P140 and Kapiglucagon carry the usual high failure rates of drug development, and execution risk is acute for a small team pursuing two programmes at once. It is also worth noting that an automated technical-analysis service currently classes the shares as a "sell candidate", a signal generated by algorithm rather than by an analyst, a reminder that not every reading of the stock is constructive.

What to watch next

The near-term signposts are clear enough. Any concrete news on P140 partnering, a signed term sheet, a named counterparty or milestone payments, would be the single most important catalyst. Progress on the PCT patent filing, publication of the mechanistic manuscript, and confirmation of an FDA pre-IND meeting for Kapiglucagon would each add substance. Investors will also watch cash consumption closely to gauge how long the post-fundraising runway extends.

Outlook

ImmuPharma is a speculative situation in the truest sense: a long-dormant name with genuine, if unproven, optionality and a well-worn history of disappointing those who arrived early. The recent snapshot move and steady stream of updates suggest some investors are willing to look again. Whether that attention hardens into a sustained re-rating depends almost entirely on delivery, above all, on turning years of partnering talk into a signed deal.